Enterome announced that clinical data from the ongoing Phase 1/2 trial of EO2463 in monotherapy and in combination with lenalidomide and/or rituximab in indolent non-Hodgkin lymphoma will be presented at 2024 American Society of Clinical Oncology Annual Meeting, to take place May 31 - June 4, in Chicago, Illinois.
April 25, 2024
· 3 min read